Medicalgorithmics has signed a second commercial distribution agreement for VCAST -an AI platform for the analysis of coronary computed tomography angiography (CCTA). The Polish medtech company is expanding its collaboration with Turkish partner Ege Aritmi, which has been distributing Medicalgorithmics’ innovative AI software since March. Thanks to this new agreement, the company’s breakthrough cardiac imaging technology – which uses AI and competes with U.S.-based firms such as HeartFlow and Cleerly – will, after integration is completed, become available to clients in the promising Turkish market.
Medicalgorithmics entered the Turkish market in March of this year. It is a market with significant potential – there has been notable growth in the adoption of advanced medical devices, particularly in the fields of imaging and diagnostics. According to estimates by Statista Market Insights (2024), revenue in Turkey’s medical device market is expected to reach USD 5.4 billion in 2025. Among various segments, the largest share will belong to the cardiology device market, which is projected to be worth USD 889.16 million this year. This market is expected to grow at a compound annual growth rate (CAGR) of 5.09% between 2025 and 2029, reaching a value of USD 6.59 billion by 2029.
“The signing of a second commercial agreement for VCAST is clear evidence of the growing trust in Medicalgorithmics and the record-breaking interest in our breakthrough technologies and products. The fact that our Turkish partner decided to expand the collaboration so quickly confirms both the attractiveness of our VCAST platform and our assumption that current partners in promising markets will be interested in distributing additional innovative products. Medicalgorithmics’ acceleration is undeniable, and the record interest along with faster integration of new clients – at this stage, 4 out of 15 new clients in 2025 – allows us to assume that growth momentum will continue to increase in the coming months,” commented Dr. Kris Siemionow, CEO of Medicalgorithmics.
VCAST (Virtual Cardiac Stress Test) is a non-invasive AI-powered technology for assessing coronary artery disease (CAD). It enables diagnosis based on widely available and cost-effective coronary computed tomography angiography (CCTA) scans, analyzed by proprietary machine learning algorithms. VCAST provides physicians with a fast, non-invasive, and cost-efficient alternative to traditional diagnostic methods such as coronary angiography, which are considerably more complex, invasive, and expensive.
The VCAST software is CE-certified – obtaining this certification enables the company to commercialize the technology within the EU as well as in selected countries outside Europe. Developed by Medicalgorithmics’ U.S.-based subsidiary Kardiolytics Inc., VCAST utilizes advanced AI algorithms to analyze cardiac CT imaging and was originally introduced to Medicalgorithmics by its largest shareholder, Biofund Capital Management.